Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines

D. I. Cohen*, B. B. Davidovici, Z. Smetana, R. D. Balicer, E. Klement, E. Mendelson, M. S. Green

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Objectives: This large-scale study provides up-to-date estimates of Varicella zoster virus (VZV) age-specific seroprevalence and characteristics of VZV transmission in a representative sample of the Israeli population. Methods: In 2000-2001, 1,642 sera collected from an age-stratified general population sample were tested for VZV antibodies using an indirect IgG ELISA system. Results: The age-weighted VZV overall estimate was 90.2%. Seropositivity increased rapidly with age, from 68.9% at age 4 to 94.4% at age 7 and 96.6% at age 12 years. The highest force of infection was in the 4-5 years age group (0.548 per susceptible year) followed by the 6-9 years age group. Multivariate analysis revealed that VZV seroprevalence estimates were significantly associated with age and place of origin. The highest seroprevalence estimate was found among subjects of Eastern origin. Conclusions: The seroepidemiology of VZV in Israel shows a pattern corresponding to that described for developed European countries. This study indicates that the highest force of infection is in pre-school children. Knowledge of pre-vaccination seroepidemiology is important to evaluate the effect of vaccination programs on the epidemiology of the disease.

Original languageAmerican English
Pages (from-to)208-213
Number of pages6
Issue number4
StatePublished - Aug 2006

Bibliographical note

Funding Information:
The "NANOTRANSMED" project is co-funded by the European Regional Development Fund (ERDF) and by the Swiss Confederation and the Swiss cantons of Aargau, Basel-Landschaft and Basel-Stadt, in the framework of the INTERREG V Upper Rhine program ("Transcending borders with every project").


Dive into the research topics of 'Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines'. Together they form a unique fingerprint.

Cite this